VENUS REMEDIES Share Price

VENUS REMEDIES Share Price

NSE: VENUSREM
|
Pharmaceuticals
₹ 1,649.00
-₹6.60 (-0.4%)
1D
Last updated 24 Jul, 2026, 15:41 IST

VENUS REMEDIES Share Price Today

As of 25 Jul 2026, VENUS REMEDIES share price is ₹1,649.00. The stock opened at ₹1,639.90, compared to its previous close of ₹1,655.60. During today's trading session, VENUS REMEDIES share price moved in the range of ₹1,572.90 to ₹1,682.00, with an average price of ₹1,627.45 for the day. Looking at its last 52-week, the stock has touched a low of ₹424.00 and a high of ₹2,044.30. On the performance front, VENUS REMEDIES share price has increased by 131.24% over the last six months and is up 223.49% on a year-on-year basis.


₹1,572.90
0.40% down today
₹1,682.00
1D LOW
1D HIGH

VENUS REMEDIES Returns Calculator


Circuit
L
H
₹1,572.90
₹1,738.30
52-week
L
H
₹424.00
₹2,044.30
Mkt Cap Cr
2,240.37

P/E
19.28

P/B
3.38

ROE
15.49%

D/E
0.02

ROCE
19.85%

Div. Yield
0.60%

EPS(TTM)
74.29
Turnover
0.93

EV/EBITDA
12.58

Net Margin
0.00%

Op. Margin
0.00%

ROA
13.61%

Quick Ratio
0.00

Curr. Ratio
2.59
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Venus Remedies has not beaten FD return of 7%
Step 3 of 5
Valuation
Fairly Valued
Venus Remedies appears to be fairly valued compared to its peers
Step 3 of 5
Earnings
Neutral
Venus Remedies earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,68,842.0036.735.0514.85%0.5518.72%18.850.91%0.5610.90
Divis Laboratories1,93,860.0061.369.4016.19%0.0021.00%9.430.50%0.5898.19
Torrent Pharmaceuticals1,92,687.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,12,593.0033.553.2711.27%0.0014.95%423.360.93%0.4443.52
Zydus Lifesciences1,11,082.0017.393.2319.69%0.3520.30%3.700.11%0.3935.38
Lupin1,09,553.0019.834.7127.01%0.0327.44%3.510.78%0.61129.18
Mankind Pharma1,05,607.001.050.1212.65%0.4212.97%5.050.05%0.5449.37
Dr. Reddy's Laboratories97,364.9030.582.5611.07%0.1812.54%377.960.69%0.4138.68
Aurobindo Pharma88,508.4025.272.349.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs84,727.3060.2610.1018.21%0.4516.70%10.190.20%0.9713.72

VENUS REMEDIES Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹647.89₹601.45₹555.51₹600.18
Other Income₹20.96₹11.58₹10.32₹8.31
Total Revenue₹668.84₹613.03₹565.83₹608.49
Total Expenses₹606.93₹568.39₹527.90₹572.08
Profit Before Tax₹71.83₹44.64₹37.93₹36.41
Tax₹26.51₹16.15₹11.36-₹4.32
Profit After Tax₹45.31₹28.49₹26.57₹40.72
EPS - Basic₹33.90₹21.31₹19.88₹30.86
EPS - Diluted₹33.90₹21.31₹19.88₹30.86

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹61.87₹44.64₹37.93₹36.41
Income before WC changes₹76.83₹64.88₹61.26₹62.74
Change in Assets₹10.91-₹45.64-₹86.18-₹56.21
Change in Liabilities₹13.62₹33.53₹61.55₹34.57
Change in WC₹24.53-₹12.11-₹24.63-₹21.64
Cash flow from Operations₹86.44₹37.29₹36.63₹41.10
Cash flow from Investing-₹76.25-₹7.21-₹50.83-₹16.73
Cash flow from Financing-₹1.02-₹1.08-₹0.57-₹9.48
Total Cash Flow₹9.18₹28.99-₹14.77₹14.90
Cash (Start of the year)₹48.96₹21.21₹43.26₹28.88
Cash (End of the year)₹57.52₹48.96₹21.21₹43.26

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹264.00₹267.30₹278.25₹301.78
Current Assets₹451.72₹359.52₹322.84₹278.04
Total Assets₹715.72₹626.82₹601.08₹579.82
Current Liabilities₹136.29₹79.42₹82.57₹92.74
Net Current Asset₹315.43₹280.11₹240.26₹185.30
Non-Current Liabilities₹18.48₹59.86₹58.17₹46.63
Equity Capital₹560.95₹487.55₹460.34₹440.45
Total Equity & Liabilities₹715.72₹626.82₹601.08₹579.82

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹639.46₹575.21₹537.66₹576.71
Other Income₹20.78₹11.32₹10.17₹8.43
Total Revenue₹660.24₹586.53₹547.84₹585.14
Total Expenses₹591.08₹539.88₹507.51₹540.47
Profit Before Tax₹79.08₹46.65₹40.33₹44.67
Tax₹26.51₹16.15₹11.36-₹4.32
Profit After Tax₹52.56₹30.50₹28.96₹48.99
EPS - Basic₹39.32₹22.82₹21.67₹37.12
EPS - Diluted₹39.32₹22.82₹21.67₹37.12

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹69.16₹46.65₹40.33₹44.67
Income before WC changes₹83.17₹66.01₹62.58₹69.50
Change in Assets-₹5.74-₹16.70-₹24.98-₹24.12
Change in Liabilities₹20.59₹1.56-₹9.55-₹4.38
Change in WC₹14.86-₹15.15-₹34.53-₹28.50
Cash flow from Operations₹83.10₹35.38₹28.05₹41.00
Cash flow from Investing-₹76.20-₹6.94-₹50.81-₹16.75
Cash flow from Financing₹0.00₹0.00₹0.00-₹9.13
Total Cash Flow₹6.90₹28.44-₹22.76₹15.12
Cash (Start of the year)₹48.51₹20.07₹42.83₹27.70
Cash (End of the year)₹55.41₹48.51₹20.07₹42.83

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹277.46₹280.26₹290.70₹314.25
Current Assets₹435.75₹361.00₹318.19₹264.41
Total Assets₹713.21₹641.26₹608.89₹578.66
Current Liabilities₹105.23₹72.81₹72.67₹82.61
Net Current Asset₹330.51₹288.18₹245.53₹181.80
Non-Current Liabilities₹18.48₹59.86₹58.17₹46.63
Equity Capital₹589.49₹508.59₹478.05₹449.41
Total Equity & Liabilities₹713.21₹641.26₹608.89₹578.66
* All values are in INR Crore
Qty
Bid
4
1649
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 4
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
2
Neutral
3
Bullish
3
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict

RSI (14)
46.54
Neutral

ATR (14)
103.41
Neutral

STOCH(9,6)
11.8
Bullish

STOCH RSI (14)
0
Bullish

ADX(9)
20.89
Bearish

UO(9)
43.37
Neutral

ROC(12)
-4.64
Bearish

WillR(14)
-84.99
Bullish
Period
Simple value
Exponential vaue

5D
1716.38
1711.22

10D
1763.47
1736.08

20D
1768.63
1732.88

50D
1565.1
1574.49

100D
1229.19
1338.4

About VENUS REMEDIES

VENUS REMEDIES Share Price
ISIN
INE411B01019
Sector Market Cap
₹ 2,240.37 Cr

Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.

VENUS REMEDIES Financial Highlights

  • Revenue: VENUS REMEDIES reported revenue of ₹782.18 crore in FY26 vs ₹668.84 crore in FY25. It showed an increase of 16.95% on a yearly basis.
  • Operating Profit: VENUS REMEDIES reported an operating profit of ₹134.16 crore in FY26 vs ₹71.82 crore in FY25. It showed an increase of 86.80% on a year-on-year basis.
  • Net Profit: VENUS REMEDIES reported a net profit of ₹102.79 crore in FY26 vs ₹45.32 crore in FY25. It showed an increase of 126.81% on a yearly basis.

VENUS REMEDIES Quarterly Result Highlights

  • VENUS REMEDIES reported revenue of ₹181.48 crore in Jun 2026, compared with ₹264.35 crore in Mar 2026, representing a decrease of 31.35% on a quarter-on-quarter (QoQ) basis.
  • VENUS REMEDIES reported an operating profit of ₹30.04 crore in Jun 2026, compared with ₹61.61 crore in Mar 2026, representing a decrease of 51.24% on a quarter-on-quarter (QoQ) basis.
  • VENUS REMEDIES reported a profit of ₹22.97 crore in Jun 2026, compared with ₹47.50 crore in Mar 2026, reflecting a decrease of 51.64% on a QoQ basis.
  • The earnings per share (EPS) of VENUS REMEDIES stood at ₹33.90 during Jun 2026.
Know more
Promoters
41.76%
FII
2.92%
Other DII
0.89%
Retail and other
54.43%
Mutual funds
0.00%
Foreign institutions - FII
Compare against other stocks
VENUS REMEDIES Share Price
VENUS REMEDIES
Pharmaceuticals
Add Stock
Add Another

FAQs on VENUS REMEDIES Share Price